Online inquiry

IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14592MR)

This product GTTS-WQ14592MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14592MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14908MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ469MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ1991MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ13771MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ10408MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ5899MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ12827MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ5163MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW